Takeda Pharmaceutical Company Limited (Japan) (External organisation)

Activity: Industry, Government and Philanthropy Engagement and PartnershipsPatentsPatent


Inhibitors of protease activated receptor-2

Abstract: The present invention relates generally to compounds capable of inhibiting Protease Activated Receptor-2 (PAR2), and uses thereof. More specifically, the present invention relates to inhibitors of PAR2, to their preparation, and to their use in the treatment of diseases and disorders mediated by PAR2 signaling.

WO2019124567A1 - WIPO (PCT)
Application PCT/JP2018/047988 events
2017-12-20 Priority to AU2017905084A
2017-12-20 Priority to AU2017905084
2018-12-19 Application filed by Takeda Pharmaceutical Company Limited
2019-06-27 Publication of WO2019124567A1

Related patent documents
AU2017905084 AU2018388104 CN111698991 EA202091524 EP3727386 US20200383985 BR112020012589 JP2021508692 CA3086458 MXMX/a/2020/006533 NZ766221
Period27 Jun 2019
Held atTakeda Pharmaceutical Company Limited (Japan), Japan
Degree of RecognitionInternational